On March 1, 2024,  Gene & Protein in Disease (GPD, Online ISSN: 2811-003X) was included in the esteemed database, Chemical Abstracts Service (CAS). This achievement stands as a significant milestone for our journal since its inception in 2022, signifying a remarkable acknowledgment of GPD within the global academic community. The CAS database is founded in 1907 as a volunteer effort to organize published chemistry research, CAS officially became a self-supporting division of the American Chemical Society in 1956. CAS is widely acknowledged as the most comprehensive and authoritative source of chemical and scientific research. CAS provides access to over 150 million records from over 100 countries, including patents, scientific articles, and conference proceedings. Please click here to learn more about CAS: https://www.cas.org/. The editorial team at GPD extends heartfelt gratitude to all esteemed members of the editorial board whose contributions have been instrumental in steering the journal's growth. We extend our appreciation to authors, reviewers, and readers alike for their unwavering support and profound engagement with the journal. Our pledge to provide a valuable platform for groundbreaking Gene and Protein research remains unwavering, underscored by our dedication to upholding the highest standards of publishing integrity. It is our aspiration to ascend as a premier international academic journal. GPD will continue to uphold rigorous academic standards while publishing more high-quality articles, thereby improving our academic eminence and impact. These efforts are aimed at making greater contributions to academic research and technological innovation.

  The 4th International Conference on Biomedicine and Bioinformatics Engineering (ICBBE 2024) is scheduled to held in Kaifeng, China on June 14-16, 2024. Sponsored by Henan University, ICBBE 2024 mainly focuses on Biomedicine and Bioinformatics Engineering. The conference aims at providing a platform for innovative academics, experts, engineers and students in the field of "Biomedical Imaging and Sensing", "Bioinformatics Approaches" and "Biophotonic Devices and Materials" to exchange new ideas and share research results. During the conference, we will make discussions about the trends of the latest development in related areas and make efforts to bridge the gap between R&D results and industrial applications. The purpose is to explore the key challenges and research directions in the development of Biomedicine and Bioinformatics Engineering, with a view to promoting the development and application of theories and technologies in universities and enterprises, and to establish business or research relationship for the participants, as well as to find future business partners. The conference invites domestic and foreign universities, research institutions experts, scholars, business people and other relevant personnel to attend. The participants can not only listen to the wonderful reports of well-known experts at home and abroad, but also have a face-to-face opportunity to discuss with experts and scholars from all over the world. Conference Link: www.ic-bbe.org Sponsor Organized By Supported By

We are pleased to announce that Gene & Protein in Disease (GPD, Online ISSN: ISSN: 2811-003X, Publisher: AccScience Publishing) has been listed as a journal that follows the editorial recommendations of the International Committee of Medical Journal Editors (ICMJE) on Octomber 27, 2023 (http://icmje.acponline.org/journals-following-the-icmje-recommendations/). The ICMJE is a small working group of general medical journal editors and representatives of selected related organizations working together to improve the quality of medical science and its reporting. In Oct 2023, under the application of GPD, the ICMJE listed GPD as a journal that follows the ICMJE's Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. This gave us great encouragement and confidence to develop GPD as a premier, desirable, and transparent international platform for the molecular and translational medicine. As an academic publishing platform, GPD will continuously comply with the guidelines of Committee on Publication Ethics (COPE), World Association of Medical Editors (WAME), and ICMJE, and endeavor to publish more valuable and scientific research findings to promote scientific innovation.

Gene & Protein in Disease Editorial Board - Prof. Nicola Luigi Bragazzi, Prof. William Cho and Prof. Giampaolo Merlini - were Selected as Clarivate’s 2023 Global "Highly Cited Researchers"! Please note that the order in which the Editors appear on this page is alphabetical. Prof.  Nicola Luigi Bragazzi Department of Mathematics and Statistics, University of York, Toronto, Canada Interests: public health; epidemiology; infectious disorders; vaccination   Prof.  William Cho Department of Clinical Oncology, Queen Elizabeth Hospital, 30 Gascoigne Road, Hong Kong, China Interests: Genomics; Proteomics; Drug Repurposing and Bioinformatics; Next-Generation Sequencing; Cancer Biomarker; Evidence-based Medicine; Extracellular Vesicles; MicroRNA; Molecular Diagnostics; Non-coding RNAs; Nasopharyngeal Carcinoma; Non-small Cell Lung Cancer   Prof.  Giampaolo Merlini Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy Interests: amyloidosis; renal biopsy; autoinflammatory diseases; pathology, serum; multiple myeloma; rheumatoid arthritis; chemotherapy; oncology; hematology Source: https://clarivate.com/highly-cited-researchers/

Dialogue with Professor Liang-Jun Yan, Associate Editor of Gene & Protein in Disease Journal | ASP Exclusive Interview In this interview, Gene & Protein in Disease (GPD) journal is honored to have Professor Liang-Jun Yan, the Associate Editor of the Journal and professor at the University of North Texas Health Science Center at Fort Worth, Fort Worth, United States. In this interview, Professor Liang-Jun Yan shares his vision for GPD, as well as his thoughts, suggestions and plans for the success of the journal. Interview Profile Prof. Liang-Jun Yan University of North Texas Health Science Center at Fort Worth, Fort Worth, United States Prof. Liang-Jun Yan is currently working at University of North Texas Health Science Center at Fort Worth, Fort Worth, United States. Kenneth is involved in Diabetes,Redox Biochemistry, Mitochondrial Oxidative Stress, Acute Kidney Injury  and Chronic Kidney Disease. Interview content GPD Editorial Office:  Would you please do a self-introduction? Prof. Liang-Jun Yan: I did my undergraduate study majoring in Biochemistry at Peking University. This was followed by a master degree from the Institute of Biophysics, the Chinese Academy of Sciences. I then earned my Ph.D. from the University of California at Berkeley majoring in Molecular and Cell Biology. GPD Editorial Office: Could you give us a brief description of your research that is currently under way? Prof. Liang-Jun Yan: We study oxidative stress and mitochondrial dysfunction in aging and aging-related disease. In particular, we focus on the beneficial mechanisms of oxidative stress and redox imbalance that may turn out to be therapeutic targets. Our current projects are focused on kidney aging and injuries including diabetic kidney disease and acute kidney injury. GPD Editorial Office: What do you think of GPD differ with other journals in this field? Prof. Liang-Jun Yan: Well, GPD is a newly launched journal and thus is a new player in the biomedical Science. The title of the journal seems to indicate that the journal may be not a good avenue for studies on carbohydrates and lipids. Otherwise, I can’t point out any differences between GPD and other journals that are older than GPD. GPD Editorial Office:  Could you share with us for some ideas and suggestions to promote the development of GPD? Prof. Liang-Jun Yan: It is always a challenge for a newly launched journal. I think invitation for manuscript submission by editorial board members of GPD would be a good approach. Waive or discount of publication fees would be another approach. GPD Editorial Office: : Could you share with us about the concrete measures and guiding principle for being indexed by Science Citation Index (SCI) for GPD? Prof. Liang-Jun Yan: Getting indexed by SCI takes time and there is no short cut. I would say rigorous reviews by at least two reviewers for any submitted manuscript could ensure quality control. Additionally, publication of excellent review articles would also help tremendously. GPD Editorial Office: : As an editor, what do you look for most when deciding whether a paper can be published in a journal? Prof. Liang-Jun Yan: Whether the conclusion is supported by solid data collected by methods that are reproducible. GPD Editorial Office: :Could you recommend 1-2 current hot topics related to GPD? Prof. Liang-Jun Yan: I could only suggest in the area of my research. I think oxidative stress-related genes and proteins that are beneficial for health or for therapeutical purposes should be one focus. Examples are heat shock proteins and their encoding genes. Thanks to Prof. Liang-Jun Yan for taking time out of his busy schedule to attend the interview with editorial department of GPD, and providing support and suggestions for the development of the journal. Here, we sincerely wish Prof. Yan every success in his scientific research.    

We are pleased to announce the launch of a new initiative, the Special Issue Mentor Program. This program intends to provide an opportunity for early career scientists (new faculty, postdoc graduate students, etc.) to enhance their editing, networking, and organizational skills, and to work closely with our journal to gain more editorial experience. Early career scientists who have novel ideas for new /GPD/ Special Issues will act as Guest Editors under the mentorship of an experienced scientist; this mentor could be a member from well-established research institutes or laboratories, etc. If you are interested in this opportunity, please send your Special Issue proposal to the /GPD/ Editorial Office (gpd.office@accscience.sg), and we will discuss the process (i.e., mentor collaboration, Special Issue topic feasibility analysis, etc.) in further detail. In addition to the new Special Issue Mentor Program, /GPD/ will continually welcome all Special Issue proposals based on hot research topics as usual.

Dialogue with Professor Kenneth Blum, Associate Editor of Gene & Protein in Disease Journal | ASP Exclusive Interview In this interview, Gene & Protein in Disease (GPD) journal is honored to have Professor Kenneth Blum, the Associate Editor of the Journal and professor at the Western University of Health Sciences, Division of Addiction Research & Education, Center for Sports, Exercise& Mental Health, USA. In this interview, Professor Kenneth Blum shares his vision for GPD, as well as his thoughts, suggestions and plans for the success of the journal, especially its inclusion in the Science Citation Index (SCI). Interview Profile Prof. Kenneth Blum Western University of Health Sciences, Pomona, CA, United States Prof. Kenneth Blum is currently working at Western University of Health Sciences, Pomona, CA, United States. Kenneth is involved in Genetics of Alcoholism, Nutritional Genetics, Pharmacogenetics, Neuropsychiatry, Neuropharmacology and Epigenetics.   Interview content GPD Editorial Office: Could you give us a little introduction to yourself? Prof. Kenneth Blum: Yes. It would be my pleasure. I graduated from Columbia University with a bachelor's in science in pharmacy. I then went to Seton Hall College of Medicine, that turned out to be New Jersey College of Medicine, where I got a master's degree in health Sciences. Then I went to New York Medical College then I went to New York medical college and I got a PhD in neuropharmacology. And I was also at Colorado University. I got a fellowship in genetics, and I've been doing research on substance use disorders and other behavioral addictions since 1964. GPD Editorial Office: Fantastic. Could you give us a brief description of your research that's currently underway? Prof. Kenneth Blum: Well, my research for years has been looking at the genetics and the epigenetics, potentially of all addictive behaviors, both drugs and non-drugs like gambling and other behavioral addictions. Currently, we're working with a group out of California, Kevin Murthy, Milan Makale, Keerthy Sunder's group, on the idea of using transcranial magnetic stimulation (TMS) in a personalized EEG induced signature for different types of addiction, psychiatry in general, PTSD, even trauma. So, this is one of the things we're working on. The second thing we're working on is we're looking at gene editing, the reward genes in the brain, to quote a big word, "cure" all addictive behaviors. GPD Editorial Office: That's great. What do you think of GPD as being different from other journals in this field? Prof. Kenneth Blum: Well, it's not so much different. There are so many journals in the field these days, and they all trying to do a good job. I think one thing that stood out is why I decided to join the editorial board of the journal was actually the title/Genes & Proteins in Disease/. I mean, what better way to understand what's going on with all addictive behaviors is to look at the genetics, look at the epigenetics, and then, of course, look at the therapeutics thereof involving proteins and disease. So, I think it's not so much different. It's what the focus of the journal is about. And of course, the entire publishing entity really worries about barriers in publishing involving fees and other such matters. GPD Editorial Office: That's great. Could you share with us for some ideas and suggestions to promote the development of GPD? Prof. Kenneth Blum: Well, it's very difficult in terms of promotion, and what we mean by that is that all journals are seeking to get high quality papers. One of the most important ways is to have a good editorial board. The other important way is to be involved with social media and to promote it through social media. But in terms of the scientific community, the thing is to make sure that people understand that there's a rigorous peer review for that particular journal and that it's going to try to keep up the quality of the papers that actually get published. So, it's a matter of bringing in high quality papers, rejecting those papers that are not high quality, and promoting the fact that the journal is doing a highly intellectual job in making the experience really worthwhile for the authors. GPD Editorial Office: Well said. Could you share with us about the concrete measures and guiding principle for being indexed by Science Citation Index (SCI) for GPD? Prof. Kenneth Blum: Well, the Science Citation Index is very important and most authors, when they look for a journal, they want to make sure that the journal has an impact factor and actually that are in good databases such as Citation Index. Gaining the impact factor is not an easy task, especially for a new journal. But that is the goal. And once you get an impact factor, even if it's low, as long as its official, people begin to respect the journal. So, it's very important to make sure that the journal, in the early days, actually looks at timelines. Make sure that they fill issues with at least five papers per issue, and they have a good track record for a couple of years that they actually were able to publish enough papers to have them be secure in the delivery of the publication on a timely basis. With high quality papers, of course. GPD Editorial Office: So, on that note, as an editor, what do you look for most when deciding whether a paper can be published in a journal? Prof. Kenneth Blum: Well, the first thing is the idea of peer review was not the idea to punish the authors, the idea of peer review was to help them and improve the manuscript. Now, I have published over 700 peer review papers in my career and I've sometimes received very strange peer reviews that we didn't like at all, but we had to fight and get it done. Most authors would appreciate actual criticisms that can be translated to bring about transformation of the paper and making it a much stronger paper. So, I think that's one important thing. The other important thing is that all the I's dotted the T's across and you got a really very solid publication. Whether it is a case study or an original paper or review, it has to be full of scholarly remarks that has contribution that each paper should have contribution to the field over and beyond what's been in the field in the past. GPD Editorial Office: Could you recommend 1-2 current hot topics related to GPD? Prof. Kenneth Blum: Well, one of them that I think is very important, of course it's up my alley is the whole idea of trying to utilize genetic testing. Whether it is GWAS which then gets converged to candidate genes and all of addiction psychiatry, the more we understand the genetics and whether it's the predisposition of DNA antecedents or whether it is epigenetic insults that affect transcription through messenger RNA, you need to have both of these kinds of genetic assessments. So, the hot topic would be the general addiction screening with very reliable and accurate genetic testing. The second important topic is the whole idea of pre-addiction. And pre-addiction is now a hot topic that was developed by McLellan, Koob and Volkow, basically saying that we need to get earlier identification of people that possess DNA antecedents. For example, these DNA antecedents are actually insulted by environmental epigenetics. But we have to find ways to assess pre-addiction before the addiction begins. So, in my looking at this topic, we're very excited about suggesting that the genetics of addiction can be measured by a DNA test called Genetic Addiction Risk Severity (GARS) and screening people for early identification (vulnerability) is a  hot topic. Thanks to Prof. Kenneth Blum for taking time out of his busy schedule to attend the interview with editorial department of GPD, and providing support and suggestions for the development of the journal. Here, we sincerely wish Prof. Blum every success in his scientific research. Appendix:  Please click the link below to view the original Exclusive Interview edio https://www.veed.io/view/3729e43b-6b6c-41a9-8bfd-50bf14f8e831?panel=share  

Gene & Protein in Disease (ISSN: 2811-003X) publishes rigorously peer-reviewed and high-quality original articles and authoritative reviews that focus on the latest development in multidisciplinary areas in biology and biomedicine, with an emphasis on gene and protein research. Now we are currently looking for new 1-2 Associate Editors for our journal. This is an opportunity to exchange with and learn from experts in the same field. As you may know, GPD is an international journal for molecular and translational medicine, published quarterly online by AccScience Publishing. It was launched in 2022 and has published 4 issues so far. It is covered by the Google Scholar, J-Gate, Crossref, Scilit and aims to be indexed by world-recognized databases, for example, Scopus, Singapore Book Publishers Association, PubMed and Web of Science. We have already established a very good Editorial Board: https://accscience.com/journal/GPD/about/editorial_board We encourage applications from researchers with a background in a range of subject areas (https://accscience.com/journal/GPD/about/aims_scope). Should you decide to serve on this position, you would be responsible for some of the following tasks depending on your availability: -Assisting the Editor-in-Chief in journal management;- Inviting additional scientists to join the Editorial Board;- Recommending timely topics and suggesting potential guest editors;- Publishing one paper per year, free of charge, in open access; - Promoting the journal. As we provide a low-cost publishing service in open access format, we unfortunately cannot additionally pay an honorarium. The term of the Associate Editor membership is two years and could then be renewed. We believe that your expertise together with our rigorous editorial policies can build a high-standard journal specifically dedicated to Gene and Protein research. If you are interested in becoming an Associate Editor for GPD, please send your full academic CV and a short cover letter that details your interest and enthusiasm for the position to gpd.office@accscience.sg <gpd.office@accscience.sg>, before 30th Sep 2023. We look forward to hearing from you soon. Gene & Protein in Disease Editorial Office

Gene & Protein in Disease (ISSN: 2811-003X) publishes rigorously peer-reviewed and high-quality original articles and authoritative reviews that focus on the latest development in multidisciplinary areas in biology and biomedicine, with an emphasis on gene and protein research. If you are an active researcher in the field and are passionate about participating in cutting-edge research publications, please do not hesitate to contact us about joining the board and contributing to the journal. https://accscience.com/journal/GPD The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of genetics, biochemistry, biophysics, oncology, immunology, cell biology, molecular biology, developmental biology, microbiology, neuroscience, stem cell, protein science, structural biology, regenerative medicine and translational medicine. This position is open to experts in all aspects of gene and protein research. To apply for this position, recommend potential candidates or request further information, please contact Juliana Meng (juliana.meng@accscience.com) from the Gene & Protein in Disease Editorial Office.